The fluoropyrimidine 5-fluorouracil (5-FU) is widely used in cancer treatment including colorectal and breast cancer treatments [53, 54], but resistance to that drug remains a major clinical obstacle; 5- is part of its antitumor activity and FU targets the tumor suppressor p53 and subsequently triggers the cell cycle. Here, TP53 is linked to breast carcinoma.